Progentech has signed a licensing agreement with Human Genetic Signatures (HGS) to gain access to key hospital-acquired infection targets.
Payment terms were not disclosed.
Under the terms of the agreement, HGS will develop assays for MRSA, MSSA, VRE and C difficile, which will then be further integrated into the Progentech Entura platforms.
It is anticipated that manual assays for these initial targets will be taken to the Food and Drug Administration during 2009 followed by fully integrated and automated versions of the assays in 2010.
